Clinical trial
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
NCT00085436 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00085436 |
|---|---|
| Title | DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC |
| Official title | A Phase II Study Of Autologous Tumor/DC Vaccine (DC Vaccine) Combined With Interleukin-2 (IL-2) And Interferon-α-2a (IFNα-2a) In Patients With Metastatic Renal Cell Carcinoma (RCC) |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological |
| Interventions | Aldesleukin, autologous tumor cell vaccine, recombinant interferon alfa |
| Enrollment | 18 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jun 11, 2004 |
| Last update posted | Jun 26, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: